by Clinical Neuropsychologist Online | Saturday, March 16, 2024 | Dementia
Abstract BACKGROUND With the availability of disease-modifying therapies for Alzheimer’s disease (AD), it is important for clinicians to have tests to aid in AD diagnosis, especially when the presence of amyloid pathology is a criterion for receiving treatment....
by Clinical Neuropsychologist Online | Friday, March 15, 2024 | Dementia
Abstract INTRODUCTION In 2013, the ALzheimer’s and FAmilies (ALFA) project was established to investigate pathophysiological changes in preclinical Alzheimer’s disease (AD), and to foster research on early detection and preventive interventions. METHODS We...
by Clinical Neuropsychologist Online | Friday, March 15, 2024 | Dementia
Abstract INTRODUCTION Neuroinflammation is a major contributor to the progression of frontotemporal dementia (FTD). Galectin-3 (Gal-3), a microglial activation regulator, holds promise as a therapeutic target and potential biomarker. Our study aimed to investigate...
by Clinical Neuropsychologist Online | Friday, March 15, 2024 | Dementia
Abstract INTRODUCTION Neuronal nuclei are normally smoothly surfaced. In Alzheimer’s disease (AD) and other tauopathies, though, they often develop invaginations. We investigated mechanisms and functional consequences of neuronal nuclear invagination in...
by Clinical Neuropsychologist Online | Friday, March 15, 2024 | Dementia
Abstract INTRODUCTION Alzheimer’s Prevention Initiative Generation Study 1 evaluated amyloid beta (Aβ) active immunotherapy (vaccine) CAD106 and BACE-1 inhibitor umibecestat in cognitively unimpaired 60- to 75-year-old participants at genetic risk for...
